{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:25:24Z","timestamp":1788974724329,"version":"build-2803163510"},"reference-count":12,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T00:00:00Z","timestamp":1377216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Although it is well documented that long\u2010term therapy with older antiepileptic drugs (<jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s) leads to an increase in risk for atherosclerosis, there has been only limited information regarding the vascular risk in patients who are treated with new <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s. We therefore conducted a prospective longitudinal study to assess the potential effects of new <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s on the circulatory markers for vascular risk in patients with newly diagnosed epilepsy. We recruited adult patients with epilepsy who began to receive monotherapy with one of the new <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s, including levetiracetam (<jats:styled-content style=\"fixed-case\">LEV<\/jats:styled-content>), oxcarbazepine (<jats:styled-content style=\"fixed-case\">OXC<\/jats:styled-content>), and topiramate (<jats:styled-content style=\"fixed-case\">TPM<\/jats:styled-content>). Circulatory markers of vascular risk were measured twice before and after 6 months of <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content> monotherapy. A total of 109 patients completed the study (<jats:styled-content style=\"fixed-case\">LEV<\/jats:styled-content>, n\u00a0=\u00a040; <jats:styled-content style=\"fixed-case\">OXC<\/jats:styled-content>, n\u00a0=\u00a040; <jats:styled-content style=\"fixed-case\">TPM<\/jats:styled-content>, n\u00a0=\u00a029). Six months of monotherapy resulted in significant increases in low\u2010density lipoprotein cholesterol (<jats:styled-content style=\"fixed-case\">LEV<\/jats:styled-content>, from 90.2 to 98.5\u00a0mg\/dl, 9.2% increase, p\u00a0=\u00a00.025; <jats:styled-content style=\"fixed-case\">OXC<\/jats:styled-content>, from 96.5 to 103.2\u00a0mg\/dl, 7.0% increase, p\u00a0=\u00a00.049), homocysteine (<jats:styled-content style=\"fixed-case\">LEV<\/jats:styled-content>, from 7.9 to 10.4\u00a0\u03bc<jats:sc>m<\/jats:sc>, 31.6% increase, p\u00a0=\u00a00.001; <jats:styled-content style=\"fixed-case\">OXC<\/jats:styled-content>, from 8.7 to 11.5\u00a0\u03bc<jats:sc>m<\/jats:sc>, 32.2% increase, p\u00a0&lt;\u00a00.001; <jats:styled-content style=\"fixed-case\">TPM<\/jats:styled-content>, from 8.3 to 12.3\u00a0\u03bc<jats:sc>m<\/jats:sc>, 48.2% increase, p\u00a0&lt;\u00a00.001), apolipoprotein <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">LEV<\/jats:styled-content>, from 63.6 to 77.4\u00a0mg\/dl, 21.7% increase; <jats:styled-content style=\"fixed-case\">OXC<\/jats:styled-content>, from 67.0 to 83.2\u00a0mg\/dl, 24.2% increase; <jats:styled-content style=\"fixed-case\">TPM<\/jats:styled-content>, from 66.7 to 84.4\u00a0mg\/dl, 26.5% increase; all p\u00a0&lt;\u00a00.001), and apolipoprotein <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\/apolipoprotein <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>1 ratio (<jats:styled-content style=\"fixed-case\">LEV<\/jats:styled-content>, from 0.51 to 0.61, 19.6% increase; <jats:styled-content style=\"fixed-case\">OXC<\/jats:styled-content>, from 0.52 to 0.67, 28.8% increase; <jats:styled-content style=\"fixed-case\">TPM<\/jats:styled-content>, from 0.50 to 0.67, 34.0% increase; all p\u00a0&lt;\u00a00.001). Serum apolipoprotein <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>1 and folate were significantly decreased in <jats:styled-content style=\"fixed-case\">TPM<\/jats:styled-content> (from 139.1 to 132.1\u00a0mg\/dl, 5.0% decrease, p\u00a0=\u00a00.014) and <jats:styled-content style=\"fixed-case\">OXC<\/jats:styled-content> (from 8.1 to 6.4\u00a0ng\/ml, 21.0% decrease, p\u00a0=\u00a00.046) groups, respectively. There were no significant changes in total cholesterol, triglyceride, high\u2010density lipoprotein cholesterol, lipoprotein(a), and vitamin <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>12 in all three groups. Our findings suggest that treatment with some new <jats:styled-content style=\"fixed-case\">AED<\/jats:styled-content>s might be associated with alterations in circulatory markers of vascular risk, which could contribute to the acceleration of atherosclerosis and increased risk of vascular diseases.<\/jats:p>","DOI":"10.1111\/epi.12338","type":"journal-article","created":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T17:48:38Z","timestamp":1377280118000},"source":"Crossref","is-referenced-by-count":57,"title":["Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy"],"prefix":"10.1111","volume":"54","author":[{"given":"Dong Wook","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Neurology Konkuk University Medical Center Konkuk University School of Medicine Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo\u2010Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurology Kangwon National University Chuncheon Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young\u2010Min","family":"Shon","sequence":"additional","affiliation":[{"name":"Department of Neurology Seoul St. Mary's Hospital Catholic University of Korea Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology Korea University Guro Hospital Korea University College of Medicine Seoul Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,8,23]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02303.x"},{"key":"e_1_2_7_3_1","first-page":"e5","article-title":"Relationship between antiepileptic drugs and biological markers affecting long\u2010term cardiovascular function in children and adolescents","volume":"17","author":"Cheng LS","year":"2010","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03316.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20559"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70528-2"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2007.03.010"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.4065\/83.11.1203"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22229"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-010-0080-y"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02235.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21615"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10391"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.12338","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.12338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:35:44Z","timestamp":1696340144000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.12338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,23]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/epi.12338"],"URL":"https:\/\/doi.org\/10.1111\/epi.12338","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,23]]}}}